Rezolute is trading 5.4% up today at $4.61 as investors cautiously buy following an extreme selloff tied to the failed Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism.
- The upward move is viewed as a technical rebound and sector-supported recovery rather than being driven by new company-specific developments.
- The stock remains highly volatile as the market continues to digest the impact of the recent clinical trial failure.